Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

被引：0
作者：
Castelli, Barbara [1 ]
Tellini, Marco [1 ]
Guidi, Melina [1 ]
Di Nicola, Marco [1 ]
Giunti, Laura [1 ]
Buccoliero, Anna Maria [2 ]
Censullo, Maria Luigia [1 ]
Iacono, Alessandro [3 ]
Desideri, Isacco [4 ]
Genitori, Lorenzo [5 ]
Sardi, Iacopo [1 ]
Fonte, Carla [1 ]
机构：
[1] Meyer Childrens Hosp IRCCS, Neurooncol Dept, Florence, Italy
[2] Meyer Childrens Hosp IRCCS, Pathol Dept, Florence, Italy
[3] Meyer Childrens Hosp IRCCS, Radiol Dept, Florence, Italy
[4] Careggi Hosp, Radiotherapy Dept, Florence, Italy
[5] Meyer Childrens Hosp IRCCS, Neurosurg Dept, Florence, Italy
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词：
high-grade glioma; MEK inhibitors; target therapy; dabrafenib; trametinib; pleomorphic xanthoastrocytoma; BRAFV600E; BRAF inhibitors; PLEOMORPHIC XANTHOASTROCYTOMA; BRAF; INHIBITION; ADULTS;
D O I：
10.3389/fonc.2024.1359093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 BRAFV600E mutated. Due to very poor prognosis, there are a few described cases of high-grade glioma (HGG) patients treated with the combined target therapy as third-line treatment. The emergence of optimized sequencing strategies and targeted agents, including multimodal and systemic therapy with dabrafenib plus trametinib, will continue to broaden personalized therapy in HGG improving patient outcomes.
引用
收藏
页数：6
相关论文
共 35 条
  • [1] Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations
    Aggarwal, Payal
    Luo, Wen
    Pehlivan, Katherine C. C.
    Hoang, Hai
    Rajappa, Prajwal
    Cripe, Timothy P. P.
    Cassady, Kevin A. A.
    Lee, Dean A. A.
    Cairo, Mitchell S. S.
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [2] Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
    Arbour, Gabrielle
    Ellezam, Benjamin
    Weil, Alexander G.
    Cayrol, Romain
    Vanan, Magimairajan Issai
    Coltin, Hallie
    Larouche, Valerie
    Erker, Craig
    Jabado, Nada
    Perreault, Sebastien
    [J]. NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [3] FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma
    Barbato, Michael I.
    Nashed, Jeannette
    Bradford, Diana
    Ren, Yi
    Khasar, Sachia
    Miller, Claudia P.
    Zolnik, Banu S.
    Zhao, Hong
    Li, Yangbing
    Bi, Youwei
    Shord, Stacy S.
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Scepura, Barbara
    Al-Matari, Raniya A.
    Pazdur, Richard
    Kluetz, Paul G.
    Donoghue, Martha
    Singh, Harpreet
    Drezner, Nicole
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (02) : 263 - 268
  • [4] Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series
    Buccoliero, Anna Maria
    Giunti, Laura
    Moscardi, Selene
    Castiglione, Francesca
    Provenzano, Aldesia
    Sardi, Iacopo
    Scagnet, Mirko
    Genitori, Lorenzo
    Caporalini, Chiara
    [J]. GENES, 2022, 13 (04)
  • [5] The MAPK Pathway Across Different Malignancies: A New Perspective
    Burotto, Mauricio
    Chiou, Victoria L.
    Lee, Jung-Min
    Kohn, Elise C.
    [J]. CANCER, 2014, 120 (22) : 3446 - 3456
  • [6] Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study
    Cacchione, Antonella
    Fabozzi, Francesco
    Carai, Andrea
    Colafati, Giovanna Stefania
    del Baldo, Giada
    Rossi, Sabrina
    Diana, Martino
    Megaro, Giacomina
    Milano, Giuseppe Maria
    Macchiaiolo, Marina
    Crocoli, Alessandro
    De Ioris, Maria Antonietta
    Boccuto, Luigi
    Secco, Domitilla Elena
    Zama, Mario
    Agolini, Emanuele
    Toma, Paolo
    Mastronuzzi, Angela
    [J]. CANCER CONTROL, 2023, 30
  • [7] Implantation of carmustine wafers (Gliadel®) for high-grade glioma treatment. A 9-year nationwide retrospective study
    Champeaux, Charles
    Weller, Joconde
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (01) : 159 - 169
  • [8] Primary anaplastic pleomorphic xanthoastrocytoma in adults. Case report and review of literature
    Choudry, Usama Khalid
    Khan, Saad Akhtar
    Qureshi, Amjad
    Bari, Ehsan
    [J]. INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2016, 27 : 183 - 188
  • [9] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
    Flaherty, Keith T.
    Infante, Jeffery R.
    Daud, Adil
    Gonzalez, Rene
    Kefford, Richard F.
    Sosman, Jeffrey
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Ibrahim, Nageatte
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald
    Algazi, Alain
    Lewis, Karl
    Long, Georgina V.
    Puzanov, Igor
    Lebowitz, Peter
    Singh, Ajay
    Little, Shonda
    Sun, Peng
    Allred, Alicia
    Ouellet, Daniele
    Kim, Kevin B.
    Patel, Kiran
    Weber, Jeffrey
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) : 1694 - 1703
  • [10] The functional role of p38 MAPK pathway in malignant brain tumors
    Grave, Nathalia
    Scheffel, Thamiris Becker
    Cruz, Fernanda Fernandes
    Rockenbach, Liliana
    Goettert, Marcia Ines
    Laufer, Stefan
    Morrone, Fernanda Bueno
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
1234